Clinical adverse events included grade 1 (G1) short-term and self-limiting headache in patients 3, 7, 9, and 10 within 12 h after treatment, and moderate headache (grade 2 [G2]) in patient 9. There was a seve...
Further work should be undertaken to define the settings where 68Ga-FAP-2286 PET may inform clinical decision making, and which pts may benefit from FAP-targeted radioligand therapy. Clinical trial information: NCT04621435.doi:10.1200/jco.2022.40.16_suppl.3059T. Hope...